Kaiyi Bio is a target protein research and development platform, focusing on protein tools in the immunotherapy and diagnostic technology markets. It has a unique innovative functional recombinant protein and antibody research and development and production platform Structure Aided design and Multiplex Screening SAMSTM, focusing on global innovative drug research and development companies. Customers, provide functional target proteins based on structural design, especially membrane proteins, CRO services and catalog products. Recently, Kaiyu Biotech announced the completion of a Series B financing transaction of nearly 200 million yuan. This round of financing was led by Lianxin Capital, with Lingang Blue Bay Capital, Guofang Capital and a well-known multinational life science industry group participating in the investment.
This article is reproduced from: https://www.itjuzi.com/investevent/13613781
This site is for inclusion only, and the copyright belongs to the original author.